The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells

Cancer Research

Volumn 61, Issue 17, 2001, Pages 6555-6562

  Jacob, Sandrine ^a   Aguado, Mélanie ^a   Fallik, David ^a   Praz, François ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOUBLE STRANDED DNA; ETOPOSIDE; PROTEIN P53;

APOPTOSIS; ARTICLE; BASE MISPAIRING; CELL CYCLE; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG SENSITIVITY; GENE DELETION; GENE INSERTION; HUMAN; HUMAN CELL; MICROSATELLITE INSTABILITY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE PAIR MISMATCH; CAMPTOTHECIN; CARRIER PROTEINS; CELL CYCLE; COLORECTAL NEOPLASMS; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; MUTS HOMOLOG 2 PROTEIN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; RETROSPECTIVE STUDIES; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035418619     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. DNA topoisomerases
2. Topoisomerase I poisons and suppressors as anticancer drugs
3. Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice
4. Topoisomerase poisons: Harnessing the dark side of enzyme mechanism
5. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
6. Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions
7. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells
8. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
9. 2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells
10. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae
11. Mismatch repair defects in cancer
12. Microsatellite instability in human cancer: A prognostic marker for chemotherapy?
13. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage
14. 2 cell cycle checkpoint
15. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer
16. Correction of hypermutability. N-methyl-N′-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6
17. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents
18. Mammalian DNA mismatch repair
19. Eukaryotic DNA mismatch repair
20. Mediating mismatch repair
21. Multiple functions of MutS- and MutL-related heterocomplexes
22. Multiple pathways or recombination induced by double-strand breaks in Saccharomyces cerevisiae
23. DNA mismatch repair and genetic instability
24. Mismatch repair processing of carcinogen-DNA adducts triggers apoptosis
25. Apoptosis induced by overexpression of hMSH2 or hMLH1
26. hMSH2 forms specific mispair binding complexes with hMSH3 and hMSH6
27. Isolation of MutSβ from human cells and comparison of the mismatch repair specificities of MutSβ and MutSα
28. Signaling mismatch repair in cancer
29. DNA mismatch repair genes and colorectal cancer
30. Germ-line msh6 mutations in colorectal cancer families
31. Clues to the pathogenesis of familial colorectal cancer
32. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis
33. Microsatellite instability in cancer of the proximal colon
34. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer
35. Responsiveness of metastatic colorectal cancers to chemotherapy with CPT11(irinotecan): Possible role of the DNA mismatch repair
36. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation
37. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines
38. Genetic instability in colorectal cancers
39. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay
40. Characterization of rhodamine 123 binding to P-glycoprotein in human multidrug-resistant cells
41. Cell cycle regulation of the human DNA mismatch repair genes hMSH2, hMLH1, and hPMS2
42. Topoisomerase 1-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute cancer screen
43. The human MLH1 cDNA complements DNA mismatch repair defects in mlhl-deficient mouse embryonic fibroblasts
44. Growth suppression mediated by transfection of wild-type hMLH1 in human cancer cells expressing endogenous truncated HMLH1 protein
45. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability
46. Mutation of a mutL homolog in hereditary colon cancer
47. Characterization of the topoisomerase 1 locus in human colorectal cancer
48. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
49. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein
50. Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells
51. Lessons from hereditary colorectal cancer
52. Spontaneous development of drug resistance: Mismatch repair and p53 defects in resistance to cisplatin in human tumor cells
53. Close correlation between mutations of E2F4 and hMSH3 genes in colorectal cancers with microsatellite instability
54. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation
55. 2-M cell cycle checkpoint arrest following ionizing radiation
56. Stress signals utilize multiple pathways to stabilize p53
57. waf-1/cip-1 and Mdm2 by etoposide: Etoposide inhibits the p53-Mdm2 autoregulatory feedback loop
58. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status
59. Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colonadenocarcinoma cell lines
60. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
61. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures
62. Immortalization and characterization of Nijmegen Breakage Syndrome fibroblasts
63. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes
64. Effects of topoisomerase II inhibition in lymphoblasts from patients with progeroid and "chromosome instability" syndromes
65. ATM-dependent phosphorylation of nibrin in response to radiation exposure